fruquintinib + camrelizumab + paclitaxel liposome + nedaplatin

This is a four-drug combination regimen consisting of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin.\n**Fruquintinib** is a highly selective small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1/2/3), thereby inhibiting angiogenesis and tumor blood vessel maturation[1][3][4][5].\n**Camrelizumab** is a humanized monoclonal antibody that targets the programmed cell death protein 1 receptor (PD-1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses.\n**Paclitaxel liposome** is a nanoparticle formulation of the microtubule-stabilizing chemotherapeutic agent paclitaxel; encapsulation in liposomes improves drug delivery and reduces toxicity compared to conventional formulations[6][8].\n**Nedaplatin** is a second-generation platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis with reduced nephrotoxicity compared to cisplatin[6][8].\n\nThis combination has been studied as first-line therapy for advanced esophageal squamous cell carcinoma (ESCC) in phase II clinical trials. The regimen demonstrated significant efficacy and manageable toxicity profiles in this setting[10].

Brand names

Fruzaqla (fruquintinib)

Other names

FRUZAQLA (fruquintinib)SHR1210 (camrelizumab, code name)Lipusu (paclitaxel liposome, common brand in China)